Literature DB >> 34078743

First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes.

Jenna J Guthmiller1, Julianna Han2, Lei Li3, Alec W Freyn4, Sean T H Liu4, Olivia Stovicek3, Christopher T Stamper5, Haley L Dugan5, Micah E Tepora3, Henry A Utset3, Dalia J Bitar3, Natalie J Hamel3, Siriruk Changrob3, Nai-Ying Zheng3, Min Huang3, Florian Krammer4, Raffael Nachbagauer4, Peter Palese4,6, Andrew B Ward7, Patrick C Wilson1,5.   

Abstract

Broadly neutralizing antibodies are critical for protection against both drifted and shifted influenza viruses. Here, we reveal that first exposure to the 2009 pandemic H1N1 influenza virus recalls memory B cells that are specific to the conserved receptor-binding site (RBS) or lateral patch epitopes of the hemagglutinin (HA) head domain. Monoclonal antibodies (mAbs) generated against these epitopes are broadly neutralizing against H1N1 viruses spanning 40 years of viral evolution and provide potent protection in vivo. Lateral patch-targeting antibodies demonstrated near universal binding to H1 viruses, and RBS-binding antibodies commonly cross-reacted with H3N2 viruses and influenza B viruses. Lateral patch-targeting mAbs were restricted to expressing the variable heavy-chain gene VH3-23 with or without the variable kappa-chain gene VK1-33 and often had a Y-x-R motif within the heavy-chain complementarity determining region 3 to make key contacts with HA. Moreover, lateral patch antibodies that used both VH3-23 and VK1-33 maintained neutralizing capability with recent pH1N1 strains that acquired mutations near the lateral patch. RBS-binding mAbs used a diverse repertoire but targeted the RBS epitope similarly and made extensive contacts with the major antigenic site Sb. Together, our data indicate that RBS- and lateral patch-targeting clones are abundant within the human memory B cell pool, and universal vaccine strategies should aim to drive antibodies against both conserved head and stalk epitopes.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34078743     DOI: 10.1126/scitranslmed.abg4535

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  7 in total

1.  Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.

Authors:  Maya Sangesland; Alba Torrents de la Peña; Seyhan Boyoglu-Barnum; Larance Ronsard; Faez Amokrane Nait Mohamed; Thalia Bracamonte Moreno; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; Musie Ghebremichael; Masaru Kanekiyo; Andrew Ward; Daniel Lingwood
Journal:  Immunity       Date:  2022-08-10       Impact factor: 43.474

2.  The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.

Authors:  Kaito Nagashima; John V Dzimianski; Julianna Han; Nada Abbadi; Aaron D Gingerich; Fredejah Royer; Sara O'Rourke; Giuseppe A Sautto; Ted M Ross; Andrew B Ward; Rebecca M DuBois; Jarrod J Mousa
Journal:  J Immunol       Date:  2022-06-13       Impact factor: 5.426

3.  Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens.

Authors:  Lei Li; Siriruk Changrob; Yanbin Fu; Olivia Stovicek; Jenna J Guthmiller; Joshua J C McGrath; Haley L Dugan; Christopher T Stamper; Nai-Ying Zheng; Min Huang; Patrick C Wilson
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 13.994

4.  Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants.

Authors:  Jenny E Hernandez-Davies; Emmanuel P Dollinger; Egest J Pone; Jiin Felgner; Li Liang; Shirin Strohmeier; Sharon Jan; Tyler J Albin; Aarti Jain; Rie Nakajima; Algimantas Jasinskas; Florian Krammer; Aaron Esser-Kahn; Philip L Felgner; Qing Nie; D Huw Davies
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

5.  Researchers getting closer to a "universal" flu vaccine.

Authors:  Carolyn Beans
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-01       Impact factor: 12.779

Review 6.  B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.

Authors:  Jenna J Guthmiller; Henry A Utset; Patrick C Wilson
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

7.  Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components.

Authors:  Jenny E Hernandez-Davies; Jiin Felgner; Shirin Strohmeier; Egest James Pone; Aarti Jain; Sharon Jan; Rie Nakajima; Algimantas Jasinskas; Erwin Strahsburger; Florian Krammer; Philip L Felgner; D Huw Davies
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.